AINDEX
Markets

Regentis Biomaterials Ltd. (RGNT)

RGNTAMEXIndustrial Specialties

$1.19

-0.0400 (-3.25%) today

Closed, Nov 16, 3:59 PM ET

-3.25% 1D
Market cap
$8.64m
P/E
–
EPS, last 4 quarters
–
Dividend yield
–
Day range
–
52-week range
$1.16 to $15.50
Average volume
–
Previous close
$1.23

Earnings

Next report

Financials

QuarterDec 2022
Revenue–
Gross profit–
Operating income-$1.41m
Net income-$1.45m

News

5 latest

The company

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

Sector
Health Care
Industry
Industrial Specialties
Exchange
AMEX
Region
Middle East

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.